Consultant Rheumatologist and Metabolic Bone Physician
Cambridge University Hospitals
Clinical Lead Spondyloarthritis
Co-Director Eastern Rare Bone Network (ERBoN)
ECTS Committee Rare Disease Action Group
Dr. Clunie has worked in Rheumatology for 35yrs. He first gained an interest in Spondyloarthritis (SpA) looking at B27 prevalence in isolated communities in 1987, then working with Dr Andrew Keat who was, at the time working in Professor Derek Brewerton’s Department. Over the years, he has merged his clinical interest in SpA with his Metabolic Bone interest, which has developed since the 1990s when he was Clinical Lead for The UK’s first, and then only, DXA Scanning Unit.
Dr. Clunie’s MD was based in Nuclear Medicine, primarily studying the delivery to, and measurement of effect of, internal therapeutic radiation to joint synovium, under the supervision of Prof. Jo Edwards (who proposed, and was the first to show, the use of rituximab for RA) at UCLH.
More latterly, Dr. Clunie’s group showed, for the first time, the positive effect of zoledronate on axSpA spinal osteitis; also, he and colleagues, have published on the complexity of effects in SpA on bone and bone-potential tissues. Currently, he is investigating, with Radiology colleagues (Prof. Andrew Grainger) on aspects of radiological interpretation of psoriatic MSK and bone diseases and is Clinical Lead for SpA in Cambridge.
Dr. Clunie now also heads up the regional rare bone disease service; a subject on which he has advised NHSE and ECTS and has co-lead at CRG. His Unit in the UK is one of the few worldwide who manage XLH patients with Burosumab (anti-FGF23). Dr Clunie leads research on XLH and the FGF23-related condition Tumor-Induced Osteomalacia (TIO).
Dr. Clunie is senior, longest serving and original author-editor of the popular Oxford Handbook of Rheumatology and is Co-Author of the Rheumatology Chapter of Davidson’s Principles and Practice of Medicine. He is a keen tennis player and Mountain Biker.